BTK and lymphoma: The co-targeting of these two proteins using [Au(d2pype)2]Cl and ibrutinib may be more effective in this type of lymphoma, since the ABC-DLBCL subtype has high expression and constitutive activity of NF-κB [72], and both TrxR and BTK can activate the NF-κB pathway.